MindTrace Platform for Functional Brain Mapping Data Collection
This non-therapeutic study aims to collect prospective neurocognitive and imaging data before, during, and after surgery.
This is a non-randomized, single-arm feasibility clinical trial to build and validate a technology platform to collect, analyze, and co-register multimodal data across time and multiple study sites. All participants will undergo standard-of-care therapy for their brain tumor diagnosis, from which data will be retrospectively and prospectively collected. In addition, patients will be assessed pre- and post-operatively using a battery of neuropsychological tests for language function and their mental health. These data will be recorded and co-registered in a centralized location for the validation of the MindTrace platform.
This study is the first to coordinate and collect perioperative data related to functional brain mapping, patient neuropsychological performance, and structural MRIs longitudinally within patients and across patients on a multicenter level.
- Between 18 and 90 years old.
- English-speaking.
- Able to understand study procedures and to comply with them for the entire length of the study.
- Ability of individual or legal guardian/representative to understand a written informed consent document and the willingness to sign it.
- Diagnosed with a suspected glioma (WHO grade 1-4) and consulted for an awake craniotomy with language mapping.
- Contraindication to any study-related procedure or assessment.
- Surgical pathology consistent with a diagnosis other than a WHO grade 1, 2, 3, or 4 glioma.
